The Australian Multiple Sclerosis (MS) Immunotherapy Study: A Prospective, Multicentre Study of Drug Utilisation Using the MSBase Platform

• Vilija G. Jokubaitis ,

  * E-mail: vilija.jokubaitis@unimelb.edu.au

  Affiliations Melbourne Brain Centre (RMH), Department of Medicine, The University of Melbourne, Parkville, Victoria, Australia, Department of Neurology, Royal Melbourne Hospital, Parkville, Victoria, Australia

  ⨯
• Tim Spelman,

  Affiliation Department of Neurology, Royal Melbourne Hospital, Parkville, Victoria, Australia

  ⨯
• Jeannette Lechner-Scott,

  Affiliations Department of Neurology, John Hunter Hospital, Newcastle, New South Wales, Australia, Hunter Medical Research Institute, University of Newcastle, Newcastle New South Wales, Australia

  ⨯
• Michael Barnett,

  Affiliation Brain Mind Research Institute, Sydney, New South Wales, Australia

  ⨯
• Cameron Shaw,

  Affiliation Department of Neuroscience, Geelong Hospital, Geelong, Victoria, Australia

  ⨯
• Steve Vucic,

  Affiliation Department of Neurology, Westmead Hospital, Westmead, New South Wales, Australia

  ⨯
• Danny Liew,

  Affiliation Melbourne Brain Centre (RMH), Department of Medicine, The University of Melbourne, Parkville, Victoria, Australia

  ⨯
• Helmut Butzkueven ,

  Contributed equally to this work with: Helmut Butzkueven, Mark Slee

  Affiliations Melbourne Brain Centre (RMH), Department of Medicine, The University of Melbourne, Parkville, Victoria, Australia, Department of Neurology, Royal Melbourne Hospital, Parkville, Victoria, Australia, Department of Neurology, Box Hill Hospital, Monash University, Box Hill, Victoria, Australia

  ⨯
• Mark Slee ,

  Contributed equally to this work with: Helmut Butzkueven, Mark Slee

  Affiliation Flinders University and Medical Centre, Adelaide, South Australia, Australia

  ⨯
• on behalf of the Australian MSBase Study Group

  ¶Membership of the Australian MSBase Study Group is provided in the Acknowledgments.

  ⨯